CAPR
Capricor TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The core bull case is that deramiocel is already in active FDA review with a defined August 22, 2026 decision date, HOPE-3 hit primary and key secondary endpoints, the manufacturing site is operational, and cash of about $318 million gives runway through 2027 [#8-K-2026-03-12].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.6.
What can break
Cash runway is solid through 2027, but further delays could eventually revive dilution risk.
Momentum
64
Value
41
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $31.00 · Bull $50.00 · Bear $16.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $50.80
Why
Momentum64 · Δ7d -8.1
Value41 · Δ7d +0.1
Sentiment67 · Δ7d +4.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
64
34% active weight
Current posture
7d trendSoftening
Δ7d
-8.1
Δ21d
-25.7
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
67
33% active weight
Current posture
7d trendImproving
Δ7d
+4.6
Δ21d
+20.3
Why this grade
Composite grade B. Momentum 64.4 / Value 41.1 / Sentiment 66.9
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.65B
Beta
0.39
Shares Out
45.72M
P/E (TTM) · Derived
-31.4
P/S (TTM)
101.91
P/FCF (TTM) · Derived
-24.00
Rev YoY
-100.0%
EPS YoY
-41.6%
Gross Margin
-
Op Margin
-778.8%
Net Debt
-$148.14M
Current Ratio
3.59
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology